AdvanCell: Series D

Funding

Weekly digest by email

Announced Jul 15, 2026

$315MSeries D

Reported in USD

Financing: equity
Stage group: Series C+
Country: Australia
Sectors: Biotech · Healthtech

Investors

AbingworthRole not disclosed

Ally Bridge GroupRole not disclosed

Alpha WaveRole not disclosed

Bain Capital Life SciencesRole not disclosed

Brandon CapitalRole not disclosed

Catalio Capital ManagementRole not disclosed

Eli Lilly and CompanyRole not disclosed

Eventide Asset ManagementRole not disclosed

Fidelity Management & Research CompanyRole not disclosed

MorningsideRole not disclosed

Piper HeartlandRole not disclosed

Proto AxiomRole not disclosed

Sanofi VenturesRole not disclosed

SV Health InvestorsRole not disclosed

SymBiosisRole not disclosed

TenmileRole not disclosed

Time BioVenturesRole not disclosed

T. Rowe Price AssociatesRole not disclosed

Velosity CapitalRole not disclosed

AAdvanCellCompany profile · 1 round→

Funding history

Jul 15, 2026Series D · This round$315M

Sources

businesswire.com

Similar rounds

All Biotech rounds →

Metriport

Open-source healthcare data infrastructure unifying patient records for clinicians

$26MSeries A · Aug 27, 2026

AusperBio

Develops oligonucleotide therapeutics targeting chronic hepatitis B

$120MSeries C · Aug 27, 2026

ProFound Therapeutics

Uses AI and proteomics to discover drug targets and biomarkers for preeclampsia and eclampsia

$35MStrategic · Aug 27, 2026

Arintra

AI platform automating medical coding and revenue assurance for health systems

$25MSeries B · Aug 26, 2026

Funding history

Sources

Similar rounds

Related